{"id":"W2891836054","doi":"10.1111/bjd.17195","title":"Granulocyte–macrophage colony‐stimulating factor ( <scp>GM</scp> ‐ <scp>CSF</scp> ) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti‐ <scp>GM</scp> ‐ <scp>CSF</scp> monoclonal antibody","year":2018,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; Dermatrials Research; Probity Medical Research","funders":"Department of Medicine, University of Toronto; University of Toronto; Gentofte Hospital; Takeda Pharmaceutical Company","keywords":"Medicine; Psoriasis; Psoriasis Area and Severity Index; Placebo; Clinical endpoint; Internal medicine; Granulocyte macrophage colony-stimulating factor; Immunology; Population; Granulocyte colony-stimulating factor; Clinical trial; Monoclonal antibody; Gastroenterology; Randomized controlled trial; Antibody; Pharmacology; Cytokine; Pathology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.002465867,0.001577184,0.006182,0.001725785,0.00167686,0.0005459096,0.001362033,0.002009388,0.0001235026],"category_scores_gemma":[0.00665652,0.001599867,0.001810519,0.0011924,0.002097527,0.001170706,0.0003067426,0.002099611,0.0003697047],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004193021,"about_ca_system_score_gemma":0.0008663824,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005179343,"about_ca_topic_score_gemma":0.000225278,"domain_scores_codex":[0.9849805,0.005717851,0.004591757,0.001479691,0.0006238962,0.002606338],"domain_scores_gemma":[0.9833394,0.009987307,0.004109859,0.0007498694,0.001340028,0.000473533],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.004508008,0.003340044,0.1804595,0.0004453625,0.01371798,0.01499347,0.01498766,0.0004606556,0.742397,0.00113443,0.01833594,0.005220006],"study_design_scores_gemma":[0.5987388,0.002258274,0.1050067,0.002472249,0.004426136,0.09140514,0.006886335,0.001674324,0.1553259,0.006927441,0.02420349,0.0006751363],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9438727,0.04634135,0.001096908,0.00008730882,0.003899411,0.002663325,0.0002592928,0.0002117632,0.001567954],"genre_scores_gemma":[0.991538,0.003196365,0.00154121,0.0006194828,0.0009286877,0.000158332,0.0004732618,0.000249522,0.001295138],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5942308,"threshold_uncertainty_score":0.9996976,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02003803777489788,"score_gpt":0.2707129772893686,"score_spread":0.2506749395144707,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}